{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T12:14:05Z","timestamp":1791288845813,"version":"4.3.0"},"reference-count":41,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100008746","name":"National Cancer Center","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008746","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005150","name":"Chinese Academy of Medical Sciences","doi-asserted-by":"publisher","award":["23\/136-3878"],"award-info":[{"award-number":["23\/136-3878"]}],"id":[{"id":"10.13039\/501100005150","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinical-genitourinary-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Genitourinary Cancer"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.clgc.2025.102403","type":"journal-article","created":{"date-parts":[[2025,7,21]],"date-time":"2025-07-21T23:57:04Z","timestamp":1753142224000},"page":"102403","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Expression and Prognostic Significance of Different Antibody-Drug Conjugate Target Proteins in Urachal Carcinoma"],"prefix":"10.1016","volume":"23","author":[{"given":"Tian","family":"Han","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Honglei","family":"Cui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gan","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Youyan","family":"Guan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xingang","family":"Bi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongzhe","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianzhong","family":"Shou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.clgc.2025.102403_bib0001","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1016\/j.juro.2012.06.020","article-title":"The clinical epidemiology of urachal carcinoma: results of a large, population based study","volume":"188","author":"Bruins","year":"2012","journal-title":"J Urol"},{"issue":"9","key":"10.1016\/j.clgc.2025.102403_bib0002","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1016\/j.urolonc.2016.04.012","article-title":"Clinical, prognostic, and therapeutic aspects of urachal carcinoma-A comprehensive review with meta-analysis of 1,010 cases","volume":"34","author":"Szarvas","year":"2016","journal-title":"Urol Oncol"},{"issue":"5","key":"10.1016\/j.clgc.2025.102403_bib0003","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1097\/PAS.0b013e31819aa4ae","article-title":"Urachal carcinoma: a clinicopathologic analysis of 24 cases with outcome correlation","volume":"33","author":"Gopalan","year":"2009","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.clgc.2025.102403_bib0004","doi-asserted-by":"crossref","DOI":"10.1016\/j.prp.2023.154379","article-title":"Urachal carcinoma: the journey so far and the road ahead","volume":"243","author":"Kumar","year":"2023","journal-title":"Pathol Res Pract"},{"issue":"1","key":"10.1016\/j.clgc.2025.102403_bib0005","doi-asserted-by":"crossref","first-page":"33.e11","DOI":"10.1016\/j.urolonc.2016.07.021","article-title":"Malignant urachal neoplasms: a population-based study and systematic review of literature","volume":"35","author":"Mylonas","year":"2017","journal-title":"Urol Oncol"},{"key":"10.1016\/j.clgc.2025.102403_bib0006","article-title":"Treatment outcome of different chemotherapy in patients with relapsed or metastatic malignant urachal tumor","volume":"11","author":"Chen","year":"2021","journal-title":"Front Oncol"},{"key":"10.1016\/j.clgc.2025.102403_bib0007","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2023.1199395","article-title":"Progress and prospects of targeted therapy and immunotherapy for urachal carcinoma","volume":"14","author":"Zheng","year":"2023","journal-title":"Front Pharmacol"},{"issue":"4","key":"10.1016\/j.clgc.2025.102403_bib0008","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1097\/01.ju.0000054646.49381.01","article-title":"Multimodality management of urachal carcinoma: the M. D. Anderson cancer center experience","volume":"169","author":"Siefker-Radtke","year":"2003","journal-title":"J Urol"},{"issue":"11","key":"10.1016\/j.clgc.2025.102403_bib0009","doi-asserted-by":"crossref","first-page":"2434","DOI":"10.1002\/cncr.23070","article-title":"Predictors of survival from urachal cancer: a Mayo Clinic study of 49 cases","volume":"110","author":"Molina","year":"2007","journal-title":"Cancer"},{"issue":"4","key":"10.1016\/j.clgc.2025.102403_bib0010","doi-asserted-by":"crossref","first-page":"165.e9","DOI":"10.1016\/j.urolonc.2021.09.008","article-title":"Survival benefit of chemotherapy in a contemporary cohort of metastatic urachal carcinoma","volume":"40","author":"Flammia","year":"2022","journal-title":"Urol Oncol"},{"key":"10.1016\/j.clgc.2025.102403_bib0011","article-title":"Comprehensive molecular characterization of urachal adenocarcinoma reveals commonalities with colorectal cancer, including a hypermutable phenotype","volume":"1","author":"Kardos","year":"2017","journal-title":"JCO Precis Oncol"},{"issue":"2","key":"10.1016\/j.clgc.2025.102403_bib0012","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.humpath.2013.09.008","article-title":"High-stage urachal adenocarcinoma can be associated with microsatellite instability and KRAS mutations","volume":"45","author":"Sirintrapun","year":"2014","journal-title":"Hum Pathol"},{"issue":"5","key":"10.1016\/j.clgc.2025.102403_bib0013","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1016\/j.eururo.2016.04.037","article-title":"Urachal carcinoma shares genomic alterations with colorectal carcinoma and may respond to epidermal growth factor inhibition","volume":"70","author":"Collazo-Lorduy","year":"2016","journal-title":"Eur Urol"},{"issue":"1","key":"10.1016\/j.clgc.2025.102403_bib0014","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.clgc.2023.09.002","article-title":"Clinical presentation and targeted interventions in Urachal adenocarcinoma: a single-institution case series and review of emerging therapies","volume":"22","author":"Mathavan","year":"2024","journal-title":"Clin Genitourin Cancer"},{"issue":"8","key":"10.1016\/j.clgc.2025.102403_bib0015","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1038\/s41573-023-00709-2","article-title":"Antibody-drug conjugates come of age in oncology","volume":"22","author":"Dumontet","year":"2023","journal-title":"Nat Rev Drug Discov"},{"issue":"2","key":"10.1016\/j.clgc.2025.102403_bib0016","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1038\/s41585-020-00394-5","article-title":"The biology and rationale of targeting nectin-4 in urothelial carcinoma","volume":"18","author":"Heath","year":"2021","journal-title":"Nat Rev Urol"},{"key":"10.1016\/j.clgc.2025.102403_bib0017","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2022.102351","article-title":"The evolving panorama of HER2-targeted treatments in metastatic urothelial cancer: a systematic review and future perspectives","volume":"104","author":"Patelli","year":"2022","journal-title":"Cancer Treat Rev"},{"issue":"4","key":"10.1016\/j.clgc.2025.102403_bib0018","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/j.annonc.2024.01.002","article-title":"TROPHY-U-01, a phase II open-label study of sacituzumab govitecan in patients with metastatic urothelial carcinoma progressing after platinum-based chemotherapy and checkpoint inhibitors: updated safety and efficacy outcomes","volume":"35","author":"Loriot","year":"2024","journal-title":"Ann Oncol"},{"issue":"10","key":"10.1016\/j.clgc.2025.102403_bib0019","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1056\/NEJMoa2312117","article-title":"Enfortumab Vedotin and Pembrolizumab in untreated advanced urothelial cancer","volume":"390","author":"Powles","year":"2024","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.clgc.2025.102403_bib0020","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1200\/JCO.22.02912","article-title":"Efficacy and safety of Disitamab Vedotin in patients with Human epidermal growth factor receptor 2-positive locally advanced or metastatic urothelial carcinoma: a combined analysis of two phase II clinical trials","volume":"42","author":"Sheng","year":"2024","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.clgc.2025.102403_bib0021","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1053\/j.seminoncol.2012.08.011","article-title":"Urachal adenocarcinoma: a clinician's guide for treatment","volume":"39","author":"Siefker-Radtke","year":"2012","journal-title":"Semin Oncol"},{"issue":"1","key":"10.1016\/j.clgc.2025.102403_bib0022","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0022-5347(17)50167-6","article-title":"Malignant urachal lesions","volume":"131","author":"Sheldon","year":"1984","journal-title":"J Urol"},{"issue":"3","key":"10.1016\/j.clgc.2025.102403_bib0023","doi-asserted-by":"crossref","DOI":"10.1590\/s1677-5538.ibju.2024.0665","article-title":"Urachal carcinomas: a comprehensive systematic review and meta-analysis","volume":"51","author":"Suartz","year":"2025","journal-title":"Int Braz J Urol"},{"issue":"7","key":"10.1016\/j.clgc.2025.102403_bib0024","doi-asserted-by":"crossref","first-page":"326.e17","DOI":"10.1016\/j.urolonc.2023.01.018","article-title":"Clinical value of preoperative serum tumor markers CEA, CA19-9, CA125, and CA15-3 in surgically treated urachal cancer","volume":"41","author":"Stokkel","year":"2023","journal-title":"Urol Oncol"},{"key":"10.1016\/j.clgc.2025.102403_bib0025","article-title":"The prognosis and oncological predictor of urachal carcinoma of the bladder: a large scale multicenter cohort study analyzed 203 patients with long term follow-up","volume":"11","author":"Yu","year":"2021","journal-title":"Front Oncol"},{"issue":"7","key":"10.1016\/j.clgc.2025.102403_bib0026","doi-asserted-by":"crossref","first-page":"221.e1","DOI":"10.1016\/j.urolonc.2024.03.011","article-title":"Estimation of the incidence of urachal cancer: a systematic review and meta-analysis of registry-based studies","volume":"42","author":"Olah","year":"2024","journal-title":"Urol Oncol"},{"key":"10.1016\/j.clgc.2025.102403_bib0027","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.euros.2022.02.009","article-title":"Current management of urachal carcinoma: an evidence-based guide for clinical practice","volume":"39","author":"Loizzo","year":"2022","journal-title":"Eur Urol Open Sci"},{"issue":"7","key":"10.1016\/j.clgc.2025.102403_bib0028","doi-asserted-by":"crossref","first-page":"9041","DOI":"10.1002\/cam4.5639","article-title":"Clinical sequencing identifies potential actionable alterations in a high rate of urachal and primary bladder adenocarcinomas","volume":"12","author":"Varadi","year":"2023","journal-title":"Cancer Med"},{"issue":"1","key":"10.1016\/j.clgc.2025.102403_bib0029","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1186\/s12885-020-07092-w","article-title":"Ex vivo modelling of drug efficacy in a rare metastatic urachal carcinoma","volume":"20","author":"M\u00e4kel\u00e4","year":"2020","journal-title":"BMC Cancer"},{"issue":"6","key":"10.1016\/j.clgc.2025.102403_bib0030","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1016\/j.molonc.2014.05.004","article-title":"Drug resistance to targeted therapies: d\u00e9j\u00e0 vu all over again","volume":"8","author":"Groenendijk","year":"2014","journal-title":"Mol Oncol"},{"issue":"3-4","key":"10.1016\/j.clgc.2025.102403_bib0031","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1007\/s10555-013-9447-3","article-title":"Adverse reactions to targeted and non-targeted chemotherapeutic drugs with emphasis on hypersensitivity responses and the invasive metastatic switch","volume":"32","author":"Baldo","year":"2013","journal-title":"Cancer Metastasis Rev"},{"issue":"2","key":"10.1016\/j.clgc.2025.102403_bib0032","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1002\/bco2.125","article-title":"FGFR2\/3 genomic alterations and response to enfortumab vedotin in metastatic urothelial carcinoma","volume":"3","author":"Adib","year":"2022","journal-title":"BJUI Compass"},{"issue":"21","key":"10.1016\/j.clgc.2025.102403_bib0033","doi-asserted-by":"crossref","first-page":"11547","DOI":"10.3390\/ijms222111547","article-title":"Evaluation of therapeutic targets in histological subtypes of bladder cancer","volume":"22","author":"Wucherpfennig","year":"2021","journal-title":"Int J Mol Sci"},{"issue":"7","key":"10.1016\/j.clgc.2025.102403_bib0034","doi-asserted-by":"crossref","first-page":"1764","DOI":"10.1002\/ijc.31547","article-title":"Pathogenic and targetable genetic alterations in 70 urachal adenocarcinomas","volume":"143","author":"Reis","year":"2018","journal-title":"Int J Cancer"},{"issue":"2","key":"10.1016\/j.clgc.2025.102403_bib0035","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1038\/onc.2012.36","article-title":"Upregulation of Trop-2 quantitatively stimulates human cancer growth","volume":"32","author":"Trerotola","year":"2013","journal-title":"Oncogene"},{"key":"10.1016\/j.clgc.2025.102403_bib0036","doi-asserted-by":"crossref","DOI":"10.1038\/srep33658","article-title":"Impact of TROP2 expression on prognosis in solid tumors: a Systematic review and Meta-analysis","volume":"6","author":"Zeng","year":"2016","journal-title":"Sci Rep"},{"key":"10.1016\/j.clgc.2025.102403_bib0037","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1146\/annurev-med-071322-065903","article-title":"Leveraging TROP2 antibody-drug conjugates in solid tumors","volume":"75","author":"Nelson","year":"2024","journal-title":"Annu Rev Med"},{"key":"10.1016\/j.clgc.2025.102403_bib0038","doi-asserted-by":"crossref","unstructured":"A.R. Kydd, E. Chandran, N.I. Simon, et al. SMART: a phase II study of sacituzumab govitecan (SG) with or without atezolizumab immunotherapy in rare genitourinary (GU) tumors such as small cell, adenocarcinoma, and squamous cell bladder\/urinary tract cancer, renal medullary carcinoma (RMC) and penile cancer, 42(16_suppl) (2024) TPS4627-TPS4627.","DOI":"10.1200\/JCO.2024.42.16_suppl.TPS4627"},{"key":"10.1016\/j.clgc.2025.102403_bib0039","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2021.105366","article-title":"Development of bifunctional anti-PD-L1 antibody MMAE conjugate with cytotoxicity and immunostimulation","volume":"116","author":"Xiao","year":"2021","journal-title":"Bioorg Chem"},{"issue":"10","key":"10.1016\/j.clgc.2025.102403_bib0040","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2024-009710","article-title":"Novel bispecific antibody-drug conjugate targeting PD-L1 and B7-H3 enhances antitumor efficacy and promotes immune-mediated antitumor responses","volume":"12","author":"Dong","year":"2024","journal-title":"J Immunother Cancer"},{"issue":"2","key":"10.1016\/j.clgc.2025.102403_bib0041","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.cell.2015.03.030","article-title":"Immune checkpoint targeting in cancer therapy: toward combination strategies with curative potential","volume":"161","author":"Sharma","year":"2015","journal-title":"Cell"}],"container-title":["Clinical Genitourinary Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S155876732500103X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S155876732500103X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T21:31:41Z","timestamp":1762551101000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S155876732500103X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":41,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["S155876732500103X"],"URL":"https:\/\/doi.org\/10.1016\/j.clgc.2025.102403","relation":{},"ISSN":["1558-7673"],"issn-type":[{"value":"1558-7673","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Expression and Prognostic Significance of Different Antibody-Drug Conjugate Target Proteins in Urachal Carcinoma","name":"articletitle","label":"Article Title"},{"value":"Clinical Genitourinary Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clgc.2025.102403","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"102403"}}